1. Researchers from Fudan University, Shenyang Pharmaceutical University, Shanghai Normal University, and the Chinese Academy of Sciences have discovered a small-molecule inhibitor of autophagy by disrupting protein–protein interactions involving Autophagy-Related 5 (ATG5).
2. The compound, T1742, was found to block the ATG5–ATG16L1 and ATG5–TECAIR interactions in vitro and inhibit autophagy in cellular assays.
3. A batch of derivatives sharing essentially the same core moiety were synthesized and tested for their ability to disrupt PPIs involving ATG5.
The article is generally reliable and trustworthy. It provides a detailed description of the research process used to discover a small-molecule inhibitor of autophagy by disrupting protein–protein interactions involving Autophagy-Related 5 (ATG5). The authors provide evidence for their findings through in vitro binding assays and flow cytometry assays on newly synthesized compounds. They also provide molecular modeling predictions for the possible binding mode of T1742 to ATG5.
The article does not appear to be biased or one-sided as it presents both sides equally. It does not contain any unsupported claims or missing points of consideration as all claims are backed up with evidence from experiments conducted by the authors. There are no unexplored counterarguments as all potential arguments are addressed in the article. Furthermore, there is no promotional content or partiality present in the article as it is purely focused on presenting scientific findings without any bias towards any particular viewpoint or opinion. Possible risks associated with using these compounds are noted throughout the article, making it clear that further research is needed before they can be used safely in humans or animals.